

PGC Worldwide Lab Call Details

DATE: Friday, September 13, 2013

PRESENTERS:

- Dr. Andrew Brooks, Chief Operating Officer, Rutgers University Cell and DNA Repository (RUCDR), Director, Bionomics Research and Technology Center (BRTC),
- > Dr. Michael Sheldon, RUCDR Director, Stem Cell Laboratory
- > Dr. Jennifer Moore, RUCDR Associate Director, Stem Cell Laboratory

TITLE: Dr. Brooks: "RUCDR Infinite Biologics: A Resource for the Investigation of Neuropsychiatric Disorders"

Drs. Sheldon and Moore: , ""The RUCDR Stem Cell Lab: A Resource for the Investigation of Neuropsychiatric Disorders""

START: We will begin promptly on the hour. 1000 EDT - US East Coast 0700 PDT - US West Coast 1500 BST - UK 1600 CET - Central Europe 0000 AEDT – Australia (Saturday, June 22nd, 2013)

DURATION: 1 hour

TELEPHONE: PASSCODE: 275 694 38

- US Toll free: 1 866 515.2912
- International direct: +1 617 399.5126
- Toll-free number? See
 <u>http://www.btconferencing.com/btmeetme_v3/index.asp?bid=256&dialin=866 931 5634</u>
- Operators will be on standby to assist with technical issues. "*0" will get you assistance.
- This conference line can handle up to 300 participants.

Lines are Muted **NOW**

Lines have been automatically muted by operators as it is possible for just one person to ruin the call for everyone due to background noise, electronic feedback, crying children, wind, typing, etc.

Operators announce callers one at a time during question and answer sessions.

Dial *1 if you would like to ask a question of the presenter. Presenter will respond to calls as time allows.

Dial *0 if you need operator assistance at any time during the duration of the call.

UPCOMING PGC Worldwide Lab

DATE: Friday, October 11, 2013

PRESENTERS:

- **Prof. Barbara Franke**, PhD; Professor of Molecular Psychiatry, Radboud University Medical Centre in Nijmegen, The Netherlands; Co-Founder, ENIGMA Consortium
- **Dr. Paul Thompson ;** Associate Dean for Research, University of Southern California ; Professor of Neurology & Psychiatry, Imaging Genetics Center / LONI, UCLA School of Medicine; Co-Founder, ENIGMA Consortium

TITLE: "The ENIGMA Consortium – Exploring the Genetic Architecture of Human Brain Structure"

START: We will begin promptly on the hour.

1000 EDT - US East Coast 0700 PDT - US West Coast 1500 BST - UK 1600 CEST - Central Europe 0000 AEST – Australia (Saturday, August 10th, 2013)

DURATION: 1 hour

TELEPHONE: PASSCODE: 275 694 38

- US Toll free: 1 866 515.2912
- International direct: +1 617 399.5126
- Toll-free number? See http://www.btconferencing.com/globalaccess/?bid=75_public
- Operators will be on standby to assist with technical issues. "*0" will get you assistance.
- This conference line can handle up to 300 participants.

RUCDR Infinite Biologics A Resource for the Investigation of Neuropsychiatric Disorders

Dr. Andrew Brooks Chief Operating Officer, RUCDR



September 13, 2013



Mission

RUCDR Infinite Biologics enables sharing programs (DNA, RNA, cell lines, tissue and clinical data) for NIH Institutes, research advocacy groups & biotechnology corporations

- Speeding discovery of genes for complex diseases by sharing well annotated, high quality human samples
- >\$30M annual grant & contract support
 - >120 Technical Staff




Renewable BioReso

- 50,000 sq. ft. laboratory and storage space
- 9M nucleic acid samples & 6.5M cell lines
- Distribute ~ 1M samples for genomic/genetic analyses



Repository Management Operations: Enterprise Level Integration





Research Supported Worldwide



United States National Institute of Diabetes & Digestive & Kidney Diseases of the National Institutes of Health



harlan[®]



Helping you do research better

ACC ACC ACCEPTION ACCOUNTS OF AMPLIED Accademy for Medical Development and Collaboration



Memorial Sloan-Kettering 丰 Cancer Center

SFARI



SIMONS FOUNDATION AUTISM RESEARCH INITIATIVE



Targeted Analyt

Renewable BioResources.



NATIONAL INSTITUTE ON Alcohol Abuse and Alcoholism

of the NATIONAL INSTITUTES OF HEALTH





National Institute of Allergy and Infectious Diseases



Immune Tolerance Network



5 Major Program Functions

- Sample acquisition
- Processing
- Storage
- Distribution
- Analysis





Functional Essentials: Maximizing Biological Resources

- Maximal use of primary samples
 - Undefined application for downstream analyses
- Efficient processing
 - Maximizing extraction technologies to improve yield and quality
- Appropriate storage
 - Defining storage formats and temperatures to maximize storage infrastructure
- Nucleic acid amplification / Cell line establishment
 - Creating renewable resources to preserve primary sample and/or precious collections
- Appropriate distribution guidelines
 - Define needs for specific downstream applications to preserve sample resources

Targeted Anal




The RUCDR Stem Cell Laboratory A Resource for the Investigation of Neuropsychiatric Disorders

Michael Sheldon, Ph.D. RUCDR Director, Stem Cell Laboratories Associate Professor of Genetics Rutgers University sheldon@biology.rutgers.edu http://www.RUCDR.org





The Promise of iPSCs



Adapted from Wu and Hochedlinger, Nat Cell Biol. 2011 May;13(5):497-505

Renewable BioResource Targeted Analytics



Why Use iPSC to Study Mental Health Disorders?

- Diseases processes might be manifest only in cells of the brain and central nervous system
- Differentiation provides a developmental paradigm
- Disease onset often occurs later in life making human embryonic stem cells less relevant

Renewat Targ



Summary of iPSC lines generated from patients with neurological diseases

Summary of iPSC lines generated from patients with neurological diseases

Disease	Genetic mutation	Reprogramming method	Neural differentiation	Relevant phenotype	Reference
	Sporadic	Retrovirus; 4 factor	No	No	Park (6)
PD	Sporadic	Lentivirus; excisable, inducible 3/4 factor	Yes (~5% TH+)	No	Soldner (5)
	LRRK2 (G2019S)	Retrovirus; 3 factor	Yes (3–5% TH)	Yes: Elevated alpha-synuclein expression, increased sensitivity to cellular stressors	Nguyen (8)
	PINK1 (C1366T, T509G)	Retrovirus; 4 factor	Yes (10-15% TH of TUJ1)	Yes: Less recruitment of Parkin to the mitochondria	Seibler (9)
	SNCA (A53T)	Lentivirus; excisable, inducible 4 factor	Yes	No	Soldner (68) (2011)
	SOD1 (L144F)	Retrovirus, 4 factor	Yes (20% HB9)	No	Dimos (13)
ALS	VAPB (C166T)	Retrovirus, 4 factor	Yes (5% HB9)	Yes: Reduced VAPB levels in ALS8 patients	Mitne-Neto (14)
SMA	SMN	Retrovirus, 4 factor	Yes (~10% CHAT of TUJ1)	Yes: Reduced levels of SMN protein and impaired survival of motor neurons	Ebert (3)
FD	IKBKAP	Lentivirus, 4 factor	Yes (defects in neural crest differentiation)	Yes: Tissue-specific mis-splicing incomplete differentiation, reduced motility	Lee (4)
RTT	MeCP2 (1155del32, Q244X, T158M and R306C)		Yes	Yes: Fewer synapses, reduced spine density, smaller soma size, altered calcium signaling and electrophysiological defects	Marchetto (27)
	MeCP2 (△3–4, T158M, R306C)	Retrovirus; 4 factor	Yes	Yes: Smaller soma size	Cheung (24)
FXS	FMR1	Retrovirus; 4 factor	No	No	Urbach (32)
	DISC1	Episomes; 4 factors	No	No	Chiang (34)
SCZD	Sporadic	Tetracycline- inducible lentivirus; 5 factors	Yes	Yes: Decreased neuronal connectivity, neurite number, PSD95- protein levels and glutamate receptor expression	Brennand (35)

ALS, amyotrophic lateral sclerosis; FD, familial dysautonomia; FXS, fragile X; PD, Parkinson's disease; RTT, Rett syndrome; SMA, spinal muscular atrophy; SCZD, schizophrenia.

Renewab Targe

Adapted from Marchetto et al., <u>Hum Mol Genet.</u> 2011 Oct 15;20(R2):R109-15.



The NIMH Center for Collaborative Genomic Studies on Mental Disorders

Home Availat	ble Data Interviews Publications Tools About 🚨 Sign In	
Center for Coll Genomic Studie	laborative es on Mental Disorders	
LATEST AVAILABLE DATA Netherland	ds Twin Register - Distribution 2.0 is now available. This includes subje_	
Explore the Data	<u>1-2-3-4-5-6-7</u>	• What's New
 Data Overview DNA Samples by Disorder GWAS Data Sequence Data Featured Studies Clinical Trials Psychiatric GWAS Consortium The CAPS (Fr. Phoenix) Project Browse the Data Download the Data Help us improve 	<image/> <section-header><section-header><section-header><section-header></section-header></section-header></section-header></section-header>	March 22, 2012 - Netherlands Twin Register (NTR) Dist. 2.0 includes 9,123 subjects with Rutgers IDs and their families from Study 78 (number of families=3,655; total=11,900). March 14, 2012 - Added DP Dataset 6 to Depression Dist. 3.02 (STAR*D/Study 18). February 7, 2012 - Anorexia Nervosa Dist. 1.01 updates the Version 1.0 data by conforming the data to a standard format and correcting errors. February 7, 2012 - Depression Dist. 3.02 added records from Study 7, 52, and 18 (STAR*D).
The Center for Collaborative Gen	ource for induced pluripotent stem cells (iPSC) and source cells for iPSC. nomic Studies on Mental Disorders is a collaboration of <u>Rutgers University RUCDR</u> , is and the <u>University of Southern California's Information Sciences Institute</u> . It is nal Institute of Mental Health.	November 30, 2011 - Schizophrenia Dist. 8.01 added auxiliary files and dictionary. November 14, 2011 - Added seven PGC bipolar genotypes.
The Center produces, stores, and	d distributes clinical data and biomaterials (DNA samples and cell lines) available in the	October 25, 2011 - Added auxiliary files for Bipolar Disorder Dist. 6.02 - list of

Renewat


https://www.nimhgenetics.org/



NIMH-Supported Efforts Include:

- 2009-2013 (RFA-MH-09-130, ARRA, etc): generation of source cells (e.g., fibroblasts) and reprogrammed cells has occurred through individual competing research project grants rather than a unified derivation effort.
- 2011 (NOT-MH-10-024): Central repository to bank, validate & distribute iPSCs and source cells at Rutgers, integrated with NIMH Human Genetics Initiative; <u>http://nimhstemcells.org/</u>.
 - Steering Committee guides Q/C and validation processes.
 - Most lines from schizophrenia, bipolar disorder and autism spectrum disorders; first lines will be available in October 2013.
- 2012 (NOT-MH-13-002): Policy statement NIMH grantees are expected to submit source cells and reprogrammed cells to NIMH repository.
 - Consents and sharing plans stipulate centralized banking and wide distribution, including to for-profit entities.

Renewable Bi Targeted





nimhstemcells.org



mission

The purpose of the NMH Stem Cell Center is to provide a resource for postnatal-to-adult human control and patient-derived cells and their reprogrammed derivatives; this repository will support stem cell research relevant to mental disorders. This includes but is not limited to anxiety disorders, attention deficit hyperactivity disorder, autism spectrum disorders, bipolar disorder, borderline personality disorder, depression, eating disorders, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, and schizophrenia. The capabilities of the repository will range from derivation and banking of primary source cells from postnatal through adult human subject tissue to more comprehensive banking and validation of iPSCs or similar reprogrammed/de-differentiated cells.

nimh center for collaborative studies of mental disorders at rucdr



<u>RUCDR</u> is the National Institute of Mental Health (NMH) Center for Collaborative Studies of Mental Disorders. We have established cell lines and DNA for this initiative since 1998. The NMH collection now contains a vast array of samples from families with schizophrenia, bipolar disorder, Alzheimer's disease, autism, obsessivecompulsive disorder, depression, and ADHD. Many important discoveries have been made by investigators accessing these collections. There is a <u>catalog listing cells available</u> under the NMH program.

The Center for Collaborative Genomic Studies on Mental Disorders is a collaboration of <u>Rutgers University RUCDR</u>, <u>Washington</u> <u>University in St. Louis</u> and the <u>University of Southern California's Information Sciences Institute</u>. It is funded by a grant from the <u>National Institute of Mental Health</u>.

nih center for regenerative medicine

RUCDR is the host for a collection of iPSC created by the NH Center for Regenerative Medicine (CRM). There is a catalog of available lines.

rucdr



Rutgers University Cell and DNA Repository (RUCDR) plays a key role in research aimed at understanding the genetic causes of common, complex diseases. RUCDR activities will enable gene discovery leading to diagnoses, treatments and, eventually, cures for these diseases. RUCDR assists researchers throughout the world by providing the highest quality biomaterials, technical consultation, and logistical support.



news updates

2013 World Congress on Psychiatric Genetics (WCPG). We have organized a symposium entitled "Induced Pluripotent Stem Cells: Tools for the Investigation of Neuropsychiatric Disorders" to be presented at the 2013 World Congress Psychiatric Genetics on October Boston, MA. October 17-21, 2013.

We have been invited to participate in the International Coordination for Large Scale iPSCS Initiatives retreat being held at the






Disease-Specific iPSC Lines at RSCL Catalog of induced Pluripotent Stem Cell (iPSC) and Source Cells available for distribution through the NIMH Stem

Cell Resource

Study	Abstract	# of iPSC	# of	# of	Projected
#		Lines	Fibroblast	Olfactory	Release Date
			Lines	Epithelium	
				Lines	
125	<u>R33MH087840</u>	9	Approx.16		8/1/2013
116	R01MH089176	23	19		9/1/2013
115	<u>R33MH087898</u>		35		10/1/2013
115	<u>R33MH087898</u>	60	Approx. 60		10/1/2013
130	<u>R21MH093958</u>	24	50		1/1/2014
117	<u>R33MH087925</u>	8			2/1/2014
131	<u>R01MH091115</u>	Approx. 20	Approx. 20		6/1/2014
101	<u>U01MH092758</u>		Approx. 100		6/6/2015
92	RC2MH089973		35		To Be Announced
92	RC2MH089973		58		To Be Announced
127			8	9	To Be Announced
132	ZIAMH002581		181		To Be Announced
	# 125 116 115 115 130 117 131 101 92 92 92 127	#	# Lines 125 R33MH087840 9 116 R01MH089176 23 116 R01MH089176 23 115 R33MH087898 115 R33MH087898 60 130 R21MH093958 24 117 R33MH087925 8 118 R01MH091115 Approx. 20 101 U01MH092758 92 RC2MH089973 92 RC2MH089973 127	#LinesFibroblast Lines125R33MH0878409Approx.16116R01MH0891762319115R33MH08789835115R33MH08789860Approx.60130R21MH0939582450117R33MH0879258131R01MH091115Approx. 20Approx.20101U01MH092758Approx.10092RC2MH089973581278	#LinesFibroblast LinesOlfactory Epithelium Lines125R33MH0878409Approx.16116R01MH0891762319115R33MH08789835115R33MH08789860Approx.60115R33MH0878982450117R33MH0879258131R01MH091115Approx. 20Approx.20131R01MH092758Approx.100101U01MH0927583592RC2MH089973581278


Genome Engineering in Human Stem Cells





Engineered Safe Harbor Reporter Lines

- Quantitative and Sensitive
- Stable Expression
- Useful for drug screening



3 Lines available from RSCL later in 2013:


- copGFP with RMCE in C19 locus
- NanoLuc and Halotag in C13 locus
- NanoLuc and Halotag in C19 locus


Renewabl



Control NIH-CRM iPSC Lines at RSCL

NIH Center for Regenerative Medicine iPSC Lines currently in distribution at RUCDR Infinite Biologics: August 2013						
Name or Designation	Description	iPSC Reprogramming	Starting Material	Source	Currently Available	
NCRM-1	iPSC Control	Method Episomal Plasmid	CD 34+ Cord Blood	NIH CRM Lonza Contract	? Yes	
		Episomarriasinia			105	
NCRM-2	iPSC Control	Episomal Plasmid	CD 34+ Cord Blood	NIH CRM Lonza Contract	Yes	
NCRM-3	iPSC Control	Episomal Plasmid	CD 34+ Cord Blood	NIH CRM Lonza Contract	Yes	
NCRM-4	iPSC Control	Episomal Plasmid	CD 34+ Cord Blood	NIH CRM Lonza Contract	Yes	
NCRM-5	iPSC Control	Episomal Plasmid	CD 34+ Cord Blood	NIH CRM Lonza Contract	Yes	
NCRM-6	iPSC Control	Episomal Plasmid	CD 34+ Cord Blood	NIH CRM Lonza Contract	Yes	
ND1.4	iPSC Control	Episomal Plasmid	Fibroblast (ATCC)	University of Wisconsin	Yes	
ND2.0	iPSC Control	Episomal Plasmid	Fibroblast (ATCC)	University of Wisconsin	Yes	
CY2	iPSC Control	Episomal Plasmid	Blood	NIH CRM CDI Contract	Yes	
NCRM5AS1-	iPSC line with copGFP with RMCE in C19 locus	Episomal Plasmid	NCRM5	Dr. Jizhong Zou (NIH	Coming	
iCAGcGFP				CRM)	soon	
NCRM5C13-	iPSC line with NanoLuc and Halotag in C13 locus	Episomal Plasmid	NCRM5	Dr. Jizhong Zou (NIH	Coming	
iCLHN				CRM)	soon	
NCRM5AS1-	iPSC line with NanoLuc and Halotag in C19 locus	Episomal Plasmid	NCRM5	Dr. Jizhong Zou (NIH	Coming	
iCLHN				CRM)	soon	





Advantages and benefits :

- RUCDR rebanks as needed to assure continued availability
- Quality assurance
- Global distribution
- Save time and effort with MTA management done by RUCDR
- Customized terms of distribution (ie. only to academia) and timed release (ie. after publication)

Renewable BioResource

The RUCDR Stem Cell Laboratory Operational Overview

Jennifer Moore, Ph.D. Associate Director, Stem Cell Laboratory, RUCDR Assistant Professor of Genetics Rutgers University moore@biology.rutgers.edu http://www.RUCDR.org



Psychiatric Genetics Consortium Worldwide Lab Meeting, Sep. 13, 2013




Services Offered to the Stem Cell Community by RUCDR

- 1. Cryopreserve and Distribute the highest quality primary and iPS cells.
- 2. Culturing primary source cells from tissue biopsies or frozen stocks submitted for banking. Assist clients in tissue collection and shipment as needed.
- 3. Provide a resource for reprogramming primary cells to iPSC and/or propagating iPSC submitted by clients.
- 4. Establish a rigorous Quality Control workflow for all cell types.





Biopsy and Fibroblast Workflow



Renewable BioResources... Targeted Analytics




Source Cell Reprogramming

Fibroblasts	Cryopreserved	Lymphoblastoid	Olfactory
	Lymphocytes	Cell Lines	Epithelium
Episomal Vectors	Sendai Viral Vectors	Episomal Vectors	Episomal Vectors
Renewable	Semi-Renewable	Renewable	Renewable
Resource	Resource	Resource	Resource
>50	>150	>25	N/A






Reprogramming with Episomes



Renewable BioResources Targetted Analytics



Reprogramming with Sendai Viral Vectors




Moore, Sheldon & Hart (2012) BioBanking in the era of the stem cell






Quality Control – Standard Panel (Included for all lines generated)








Quality Control – Standard Panel (Included for all lines generated)









Quality Control – Standard Panel (Included for all lines generated)












Muller FJ, Schuldt BM, Williams R, Mason D, Altun G, Papapetrou EP, Danner S, Goldmann JE, Herbst A, Schmidt NO, Aldenhoff JB, Laurent LC, Loring JF. A bioinformatic assay for pluripotency in human cells. Nature Methods (8), 315-317. 2011

••• Renewable BioResourc






Muller FJ, Schuldt BM, Williams R, Mason D, Altun G, Papapetrou EP, Danner S, Goldmann JE, Herbst A, Schmidt NO, Aldenhoff JB, Laurent LC, Loring JF. A bioinformatic assay for pluripotency in human cells. Nature Methods (8), 315-317. 2011

Renewable BioReson
 Targeted Analyt.






Muller FJ, Schuldt BM, Williams R, Mason D, Altun G, Papapetrou EP, Danner S, Goldmann JE, Herbst A, Schmidt NO, Aldenhoff JB, Laurent LC, Loring JF. A bioinformatic assay for pluripotency in human cells. Nature Methods (8), 315-317. 2011

Renewable BioResou Targeted Analyti






Muller FJ, Schuldt BM, Williams R, Mason D, Altun G, Papapetrou EP, Danner S, Goldmann JE, Herbst A, Schmidt NO, Aldenhoff JB, Laurent LC, Loring JF. A bioinformatic assay for pluripotency in human cells. Nature Methods (8), 315-317. 2011


Renewable BioResou Targetee Analyti



Quality Control – Differentiation

AFP






Embryoid Bodies

Teratomas


SMA








Quality Control – Loss of Reprogramming Factors



Renewable BioResources. Targeted Analytics /



Quality Control – Loss of Reprogramming Factors



Renewable BioResources. Targeted Analytics /



iPSC Produced at Rutgers

>250 iPSC lines completed (~85 subjects)

Episomes/EBV-lymphocyte lines

- •Alcoholism
- Autism
- •Alzheimer's (86-year-old subject;
- Cells frozen 18 years ago)

Episomes/fibroblasts •Schizophrenia

> Renewable Targete

Sendai/Lymphocytes

- Addiction
- •Alcoholism
- Schizophrenia
- •Tourette's
- •TSC
- Autism



RUCDR Leadership Team and Collaborators

Andrew Brooks, PhD Technology Director & COO


Douglas Fugman, PhD Lymphocyte Lab Director

Amrik Sahota, PhD, FACMG Clinical & Regulatory Compliance Director

David Toke, PhD Biomaterials QA Director

Michael Sheldon, PhD Stem Cell Lab Director

Linda Brzustowicz, MD Phenotype Quality Director



Jay Tischfield, PhD, FFACMG Scientific Director & CEO

Jennifer Moore, PhD Stem Cell Lab Assoc. Director

Ron Hart, PhD Rutgers University Dana Witt Communications Director

Jack Schrum, AOS, BA Facilities and Logistics Director

Sanghamitra Pati, MBA Finance Director

Janet McKim Development Director

> Renewable Targete